HRP20160475T1 - Disulfidnom vezom stabilizirani funkcionalni topivi heterodimeri mhc klase ii - Google Patents
Disulfidnom vezom stabilizirani funkcionalni topivi heterodimeri mhc klase ii Download PDFInfo
- Publication number
- HRP20160475T1 HRP20160475T1 HRP20160475TT HRP20160475T HRP20160475T1 HR P20160475 T1 HRP20160475 T1 HR P20160475T1 HR P20160475T T HRP20160475T T HR P20160475TT HR P20160475 T HRP20160475 T HR P20160475T HR P20160475 T1 HRP20160475 T1 HR P20160475T1
- Authority
- HR
- Croatia
- Prior art keywords
- mhc class
- molecule
- recombinant
- chain
- cysteine residues
- Prior art date
Links
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 20
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 20
- 102000043131 MHC class II family Human genes 0.000 claims 13
- 108091054438 MHC class II family Proteins 0.000 claims 13
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 11
- 238000000034 method Methods 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 241001529936 Murinae Species 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 241000724791 Filamentous phage Species 0.000 claims 1
- 101500028288 Homo sapiens Melanin-concentrating hormone Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Claims (18)
1. Rekombinantna molekula MHC klase II, koja sadrži:
(i) cijeli ili dio vanstaničnog dijela α lanca MHC klase II;
(ii) cijeli ili dio vanstaničnog dijela β lanca MHC klase II;
pri čemu (i) i (ii) omogućuju funkcionalnu peptid-vezujuću domenu i pri čemu su (i) i (ii) povezani disulfidnom vezom između cisteinskih ostataka smještenih na α2 domeni navedenog α lanca i β2 domeni navedenog β lanca, pri čemu navedeni cisteinski ostaci nisu prisutni u nativnim MHC klase II α2 i β2 domenama, i pri čemu rekombinantna molekula ne sadrži motiv leucinskog zatvarača.
2. Rekombinantna molekula MHC klase II iz patentnog zahtjeva 1, pri čemu je navedena disulfidna veza smještena između cisteinskih ostataka pozicioniranih na Pro 96α2 – Ser 119β2 (kategorija 1), Ser 95α2 – Ser 121β2 (kategorija 2), ili Arg 94α2 – Asn 151β2 (kategorija 3) mišjeg I-E izotipa ili ekvivalentnih lokacija u alternativnom izotipu MHC klase II.
3. Rekombinantna molekula MHC klase II iz patentnog zahtjeva 1 ili patentnog zahtjeva 2, nadalje pri čemu jedan ili više od cisteinskih ostataka odgovara pozicijama 38, 42 ili 106 referentnog slijeda H-2EB*01 (SEQ ID NO:2) ili je jedan ili više od cisteinskih ostataka na ekvivalentnim lokacijama uklonjeno u alternativnom izotipu MHC klase II.;
4. Rekombinantna molekula MHC klase II, koja sadrži:
(i) cijeli ili dio vanstaničnog dijela α lanca MHC klase II;
(ii) cijeli ili dio vanstaničnog dijela β lanca MHC klase II;
pri čemu (i) i (ii) omogućuju funkcionalnu peptid-vezujuću domenu i pri čemu su (i) i (ii) povezani disulfidnom vezom između cisteinskih ostataka smještenih na α2 domeni navedenog α lanca i β2 domeni navedenog β lanca, pri čemu navedeni cisteinski ostaci nisu prisutni u nativnim MHC klase II α2 i β2 domenama, i pri čemu je navedena rekombinantna molekula izražena na površini filamentoznog faga.;
5. Rekombinantna molekula MHC klase II iz patentnog zahtjeva 4, pri čemu je navedena disulfidna veza smještena između cisteinskih ostataka pozicioniranih na Pro 96α2 – Ser 119β2 (kategorija 1), Ser 95α2 – Ser 121β2 (kategorija 2), ili Arg 94α2 – Asn 151β2 (kategorija 3) mišjeg I-E izotipa ili ekvivalentnih lokacija u alternativnom izotipu MHC klase II, i/ili pri čemu jedan ili više cisteinskih ostataka odgovara pozicijama 38, 42 ili 106 referentnog slijeda H-2EB*01 (SEQ ID NO:2) ili je jedan ili više od cisteinskih ostataka na ekvivalentnim lokacijama uklonjeno u alternativnom izotipu MHC klase II.
6. Rekombinantna molekula MHC klase II iz patentnog zahtjeva 4 ili patentnog zahtjeva 5, pri čemu je navedena rekombinantna molekula izražena kao fuzija s površinskim proteinom faga gpIII, gpVII, gpVIII ili gpIX.
7. Rekombinantna molekula MHC klase II iz bilo kojeg od patentnih zahtjeva 1 do 3, pri čemu je navedena molekula topljiva molekula.
8. Rekombinantna molekula MHC klase II iz patentnog zahtjeva 7, pri čemu je (i) ili (ii) navedene molekule fuzioniran s Fc dijelom imunoglobulina.
9. Rekombinantna molekula MHC klase II iz bilo kojeg od patentnih zahtjeva 1 do 8, pri čemu je navedena molekula multimerna.
10. Rekombinantna molekula MHC klase II iz bilo kojeg od patentnih zahtjeva 1 do 9, pri čemu su (i) i (ii) navedene molekule izvedeni iz mišje ili ljudske molekule MCH klase II, poželjno ljudske.
11. Rekombinantna molekula MHC klase II iz bilo kojeg od patentnih zahtjeva 1 do 10, pri čemu navedenu molekulu stvara bakterijski domaćin.
12. Rekombinantna molekula MHC klase II iz bilo kojeg od patentnih zahtjeva 1 do 11, pri čemu navedena disulfidna veza jedino ima značaj u stabilizaciji MHC molekule klase II.
13. Rekombinantna molekula MHC klase II iz bilo kojeg od patentnih zahtjeva 1 do 12, pri čemu je navedena molekula u mogućnosti bojiti T stanice.
14. Rekombinantna molekula MHC klase II iz bilo kojeg od patentnih zahtjeva 1 do 13, pri čemu navedena molekula nadalje sadrži peptidnu vezu s navedenom peptid-vezujućom domenom.
15. Metoda za stvaranje rekombinantne molekule MHC klase II, koja obuhvaća:
(i) cijeli ili dio vanstaničnog dijela α lanca MHC klase II;
(ii) cijeli ili dio vanstaničnog dijela β lanca MHC klase II;
pri čemu (i) i (ii) omogućuju funkcionalnu peptid-vezujuću domenu i pri čemu su (i) i (ii) povezani disulfidnom vezom između cisteinskih ostataka smještenih na α2 domeni navedenog α lanca i β2 domeni navedenog β lanca, pri čemu navedeni cisteinski ostaci nisu prisutni u nativnim MHC klase II α2 i β2 domenama, navedena metoda obuhvaća izražavanje navedene rekombinantne molekule u domaćina prokariota.
16. Metoda za identificiranje antigeničnih peptidnih epitopa koji mogu biti prepoznati od T stanica, pri čemu navedena metoda obuhvaća korake kontaktiranja rekombinantne molekule MHC klase II iz patentnog zahtjeva 14 s T staničnim receptorom i prepoznavanje vezanja navedene rekombinantne molekule MHC klase II za navedeni T stanični receptor.
17. Metoda za detektiranje antigen-specifičnih T stanica u uzorku, pri čemu navedena metoda obuhvaća korake kontaktiranja rekombinantne molekule MHC klase II iz patentnog zahtjeva 14 s navedenim uzorkom i detektiranje vezanja navedene rekombinantne molekule MHC klase II za navedene T stanice.
18. Metoda iz patentnog zahtjeva 17, pri čemu se navedena metoda koristi za detekciju prisutnosti za bolest specifičnih T stanica u uzorku i za dijagnozu prisutnosti ili odsutnosti bolesti.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30572810P | 2010-02-18 | 2010-02-18 | |
| GBGB1002730.8A GB201002730D0 (en) | 2010-02-18 | 2010-02-18 | Product |
| US31657610P | 2010-03-23 | 2010-03-23 | |
| PCT/GB2011/050325 WO2011101681A2 (en) | 2010-02-18 | 2011-02-18 | Disulphide bond-stabilized functional soluble mhc class ii heterodimers |
| EP11730044.2A EP2536746B1 (en) | 2010-02-18 | 2011-02-18 | Disulphide bond-stabilized functional soluble mhc class ii heterodimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160475T1 true HRP20160475T1 (hr) | 2016-06-03 |
Family
ID=42113985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160475TT HRP20160475T1 (hr) | 2010-02-18 | 2016-05-04 | Disulfidnom vezom stabilizirani funkcionalni topivi heterodimeri mhc klase ii |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8828379B2 (hr) |
| EP (1) | EP2536746B1 (hr) |
| JP (1) | JP5537675B2 (hr) |
| KR (1) | KR101647176B1 (hr) |
| CN (1) | CN102947330B (hr) |
| AU (1) | AU2011217027B2 (hr) |
| CA (1) | CA2789492C (hr) |
| CY (1) | CY1117697T1 (hr) |
| DK (1) | DK2536746T3 (hr) |
| ES (1) | ES2572388T3 (hr) |
| GB (1) | GB201002730D0 (hr) |
| HR (1) | HRP20160475T1 (hr) |
| HU (1) | HUE027952T2 (hr) |
| PL (1) | PL2536746T3 (hr) |
| RS (1) | RS54744B1 (hr) |
| RU (1) | RU2604813C2 (hr) |
| SI (1) | SI2536746T1 (hr) |
| WO (1) | WO2011101681A2 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| DK3167065T3 (da) * | 2014-07-09 | 2020-07-06 | Lupin Ltd | Dobbelt cistronisk bakterielt ekspressionssystem |
| WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| KR102646495B1 (ko) * | 2016-11-09 | 2024-03-12 | 유티아이 리미티드 파트너쉽 | 재조합 pMHC II형 분자 |
| NZ758485A (en) | 2017-04-27 | 2024-02-23 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| WO2020064915A1 (en) * | 2018-09-28 | 2020-04-02 | Danmarks Tekniske Universitet | High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules |
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3719033A1 (en) * | 2019-04-02 | 2020-10-07 | imusyn GmbH & Co. KG | Stabilized mhc i |
| WO2021035049A1 (en) * | 2019-08-21 | 2021-02-25 | Uti Limited Partnership | Improved recombinant pmhc molecules |
| US20210155670A1 (en) * | 2019-09-13 | 2021-05-27 | The Regents Of The University Of California | Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications |
| WO2021113297A1 (en) * | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| DE102020109447A1 (de) | 2020-04-03 | 2021-10-07 | Jacobs University Bremen Ggmbh | Synthetisches mhc-klasse-ii-protein |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| CA2263195A1 (en) * | 1996-08-16 | 1998-02-19 | President And Fellows Of Harvard College | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
| AU741130B2 (en) * | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| NZ507887A (en) * | 1998-05-19 | 2002-12-20 | Avidex Ltd | Soluble T cell receptor |
| RU2303264C2 (ru) * | 2001-02-19 | 2007-07-20 | Мерк Патент Гмбх | Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью |
| GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| EP1675607B1 (en) * | 2003-09-05 | 2015-10-21 | Oregon Health & Science University | Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| JP2008537736A (ja) * | 2005-03-18 | 2008-09-25 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子 |
| EP2476437B1 (en) * | 2006-08-11 | 2018-11-28 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in immune disorders |
| EP2097789B1 (en) * | 2006-12-01 | 2012-08-01 | Carl Zeiss SMT GmbH | Optical system with an exchangeable, manipulable correction arrangement for reducing image aberrations |
| KR101597840B1 (ko) | 2007-08-20 | 2016-02-25 | 넥스테라 에이에스 | ｐⅦ 파아지 디스플레이 |
-
2010
- 2010-02-18 GB GBGB1002730.8A patent/GB201002730D0/en not_active Ceased
-
2011
- 2011-02-18 SI SI201130815A patent/SI2536746T1/sl unknown
- 2011-02-18 HU HUE11730044A patent/HUE027952T2/en unknown
- 2011-02-18 WO PCT/GB2011/050325 patent/WO2011101681A2/en active Application Filing
- 2011-02-18 EP EP11730044.2A patent/EP2536746B1/en active Active
- 2011-02-18 DK DK11730044.2T patent/DK2536746T3/en active
- 2011-02-18 RU RU2012138302/10A patent/RU2604813C2/ru active
- 2011-02-18 RS RS20160323A patent/RS54744B1/sr unknown
- 2011-02-18 US US13/579,887 patent/US8828379B2/en active Active
- 2011-02-18 KR KR1020127024287A patent/KR101647176B1/ko active IP Right Grant
- 2011-02-18 ES ES11730044T patent/ES2572388T3/es active Active
- 2011-02-18 JP JP2012553409A patent/JP5537675B2/ja active Active
- 2011-02-18 AU AU2011217027A patent/AU2011217027B2/en active Active
- 2011-02-18 PL PL11730044T patent/PL2536746T3/pl unknown
- 2011-02-18 CN CN201180011237.4A patent/CN102947330B/zh active Active
- 2011-02-18 CA CA2789492A patent/CA2789492C/en active Active
-
2014
- 2014-07-14 US US14/331,014 patent/US9056920B2/en active Active
-
2016
- 2016-05-04 HR HRP20160475TT patent/HRP20160475T1/hr unknown
- 2016-05-11 CY CY20161100397T patent/CY1117697T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9056920B2 (en) | 2015-06-16 |
| WO2011101681A2 (en) | 2011-08-25 |
| GB201002730D0 (en) | 2010-04-07 |
| US8828379B2 (en) | 2014-09-09 |
| AU2011217027A1 (en) | 2012-09-06 |
| SI2536746T1 (sl) | 2016-09-30 |
| KR101647176B1 (ko) | 2016-08-09 |
| JP5537675B2 (ja) | 2014-07-02 |
| US20130171668A1 (en) | 2013-07-04 |
| ES2572388T3 (es) | 2016-05-31 |
| CA2789492C (en) | 2017-04-18 |
| RU2012138302A (ru) | 2014-03-27 |
| EP2536746B1 (en) | 2016-04-20 |
| DK2536746T3 (en) | 2016-05-30 |
| US20140349315A1 (en) | 2014-11-27 |
| RS54744B1 (sr) | 2016-10-31 |
| WO2011101681A3 (en) | 2011-12-08 |
| PL2536746T3 (pl) | 2016-08-31 |
| KR20130009782A (ko) | 2013-01-23 |
| JP2013519721A (ja) | 2013-05-30 |
| CN102947330A (zh) | 2013-02-27 |
| RU2604813C2 (ru) | 2016-12-10 |
| EP2536746A2 (en) | 2012-12-26 |
| CY1117697T1 (el) | 2017-05-17 |
| CN102947330B (zh) | 2015-09-16 |
| HUE027952T2 (en) | 2016-11-28 |
| AU2011217027B2 (en) | 2015-02-05 |
| CA2789492A1 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160475T1 (hr) | Disulfidnom vezom stabilizirani funkcionalni topivi heterodimeri mhc klase ii | |
| JP2013519721A5 (hr) | ||
| HRP20190970T1 (hr) | Polipeptidi koji sadrže neglikozilirani fc | |
| ES2640268T3 (es) | Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1) | |
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| RU2012112046A (ru) | Антитело против ilt17 | |
| JP2018515084A5 (hr) | ||
| JP2017512063A5 (hr) | ||
| JP2018532372A5 (hr) | ||
| ES2566133T3 (es) | Anticuerpos monoclonales de ratón anti-Aggrus | |
| CA3110602A1 (en) | Binding protein of ns1 protein | |
| Olamendi-Portugal et al. | Functional and immuno-reactive characterization of a previously undescribed peptide from the venom of the scorpion Centruroides limpidus | |
| Hilton et al. | Direct binding to antigen‐coated beads refines the specificity and cross‐reactivity of four monoclonal antibodies that recognize polymorphic epitopes of HLA class I molecules | |
| JP2018504903A5 (hr) | ||
| CA3111159A1 (en) | Ns1-binding protein | |
| CA3111163A1 (en) | Ns1-binding protein | |
| RU2017134506A (ru) | Система презентации пептидов на клеточной поверхности | |
| Park et al. | Detection of surface asialoglycoprotein receptor expression in hepatic and extra-hepatic cells using a novel monoclonal antibody | |
| Talmont et al. | Denatured G-protein coupled receptors as immunogens to generate highly specific antibodies | |
| Edholm et al. | Characterization of anti-channel catfish IgL σ monoclonal antibodies | |
| DE602006018694D1 (de) | Rekombinante Expression von Rubella E1 Hüllenproteinvarianten als Chaperon-Fusionsproteine und seine Verwendung zum Nachweis von anti-Rubella Antikörper | |
| Hsieh et al. | Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike protein | |
| MX2019003288A (es) | Proteínas de mycobacterium tuberculosis en pruebas diagnósticas y dispositivos para la detección y diagnóstico de la tuberculosis. | |
| JP2007117090A5 (hr) | ||
| Gautam et al. | Human pIgR mimetic peptidic ligand for affinity purification of IgM: Part I: Ligand design and binding mechanism |